Smither John W
- SEC CIK
- 0001559583
Latest role at each company
- NAMS NewAmsterdam Pharma Co N.V.Directoras of Sep 9, 2026
- MBX MBX Biosciences, Inc.Chief Financial Officeras of Aug 4, 2026
- GNLX GENELUX CorpDirectoras of Jul 2, 2026
- ARQT Arcutis Biotherapeutics, Inc.Chief Financial Officeras of Feb 15, 2024
- CIK 0001801777Directoras of Dec 28, 2023
Show 1 more company
- CIK 0001828522Directoras of Jun 22, 2023
Trades
Every Form 4 that lists Smither John W as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| NAMSNewAmsterdam Pharma Co N.V. | Sep 9, 20264:30 PM ET | Sep 4, 2026 | Smither John WDirector | SSaleOrdinary Shares | −1.6K | $25.32 | −$40.51K | 8.76K | −15.4% | SEC |
| GNLXGENELUX Corp | Jul 2, 20264:35 PM ET | Jul 1, 2026 | Smither John WDirector | SSaleCommon Stock | −12K | $2.9082 | −$34.9K | 91.4K | −11.6% | SEC |
| GNLXGENELUX Corp | Jun 7, 2024 | May 29, 2024 | Smither John WDirector | PPurchaseCommon Stock | +6.25K | – | – | 13.17K | +90.3% | SEC |
| GNLXGENELUX Corp | Jun 7, 2024 | May 29, 2024 | Smither John WDirector | PPurchaseCommon Stock · Derivative | +6.25K | – | – | 6.25K | – | SEC |
| GNLXGENELUX Corp | Sep 14, 2023 | Sep 13, 2023 | Smither John WDirector | SSaleCommon Stock | −900 | $20.78 | −$18.7K | 6.92K | −11.5% | SEC |